These findings suggested ARD1 as a potential therapeutic target for development of small molecule inhibitors for PCa therapy and targeting ARD1-mediated AR acetylation and AR-HSP90 dissociation as an alternative strategy to regulate AR activity for prostate cancer therapy. This evidence concerns the gene NAA10 and Familial prostate cancer.